StockData
Akari Therapeutics Plc logo

Akari Therapeutics Plc (AKTX) stock

AKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 0/30
$5.70−0.81 (-12.44%)

Close on Nov 17, 2026Market cap $11.10MP/E –Yield –

Akari Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Akari Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $4.87M, up 69.7% year over year. For fiscal 2025 it was $2.82M, down 59.7% from the year before. Over ten years it grew -7.0% a year on average. The highest annual figure on record is $23.29M in fiscal 2017.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$2.82M-59.7%
FY2024Dec 31, 2024$6.98M+28.1%
FY2023Dec 31, 2023$5.45M-43.0%
FY2022Dec 31, 2022$9.56M+4.7%
FY2021Dec 31, 2021$9.13M+3.6%
FY2020Dec 31, 2020$8.82M+0.9%
FY2019Dec 31, 2019$8.74M-25.9%
FY2018Dec 31, 2018$11.80M-49.3%
FY2017Dec 31, 2017$23.29M+34.6%
FY2016Dec 31, 2016$17.31M+198.4%
FY2015Dec 31, 2015$5.80M+258.8%
FY2014Dec 31, 2014$1.62M+26.7%
FY2013Dec 31, 2013$1.28M-14.0%
FY2012Dec 31, 2012$1.48M+76.3%
FY2011Dec 31, 2011$841.00K+240.5%
FY2010Dec 31, 2010$247.00K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$2.08M+211.4%
Q1 FY2026Mar 31, 2026$1.46M+79.5%
Q4 FY2025Dec 31, 2025$1.09M-12.9%
Q3 FY2025Sep 30, 2025$249.00K+74.1%
Q2 FY2025Jun 30, 2025$667.00K-79.9%
Q1 FY2025Mar 31, 2025$813.00K-64.3%
Q4 FY2024Dec 31, 2024$1.25M-50.3%
Q3 FY2024Sep 30, 2024$143.00K–
Q2 FY2024Jun 30, 2024$3.31M+117.5%
Q1 FY2024Mar 31, 2024$2.28M+31.7%
Q4 FY2023Dec 31, 2023$2.51M-12.0%
Q3 FY2023Sep 30, 2023-$314.00K-114.4%
Q2 FY2023Jun 30, 2023$1.52M-49.5%
Q1 FY2023Mar 31, 2023$1.73M-51.8%
Q2 FY2022Jun 30, 2022$2.85M-44.3%
Q2 FY2021Jun 30, 2021$2.18M-42.3%
Q2 FY2020Jun 30, 2020$3.02M-44.5%
Q2 FY2019Jun 30, 2019$3.59M+139.6%
Q2 FY2018Jun 30, 2018$5.12M+165.4%
Q2 FY2017Jun 30, 2017$3.78M+188.0%
Q2 FY2016Jun 30, 2016$5.44M+443.7%
Q1 FY2016Mar 31, 2016$1.50M-3.6%
Q4 FY2015Dec 31, 2015$1.93M+79.3%
Q3 FY2015Sep 30, 2015$1.31M+707.8%
Q2 FY2015Jun 30, 2015$1.00M-35.0%
Q1 FY2015Mar 31, 2015$1.55M–
Q4 FY2014Dec 31, 2014$1.08M–
Q3 FY2014Sep 30, 2014$162.58K–
Q2 FY2014Jun 30, 2014$1.54M–

More Akari Therapeutics figures

See a number that looks wrong?